<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Brompheniramine and phenylephrine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Brompheniramine and phenylephrine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Brompheniramine and phenylephrine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9070" href="/d/html/9070.html" rel="external">see "Brompheniramine and phenylephrine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12107" href="/d/html/12107.html" rel="external">see "Brompheniramine and phenylephrine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F7675109"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Brohist D [OTC] [DSC];</li>
<li>Dimaphen Children's [OTC] [DSC];</li>
<li>Dimetapp Children's Cold &amp; Allergy [OTC];</li>
<li>Glenmax PEB [OTC];</li>
<li>Ru-Hist D [OTC];</li>
<li>Rynex PE [OTC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F987380"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihistamine/Decongestant Combination</span></li></ul></div>
<div class="block dop drugH1Div" id="F7677173"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Safety and efficacy for the use of cough and cold products in infants and young children is limited; the AAP warns against the use of these products for respiratory illnesses in infants and young children; the FDA does not recommend OTC use in infants and children &lt;2 years of age due to the risk of serious and life-threatening adverse effects (including death) and recommends to use with caution in pediatric patients ≥2 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-FDA.1'])">Ref</a></span>). Multiple concentrations of oral liquid formulations exist; close attention must be paid to the concentration when ordering or administering.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1de8fc39-12ec-4c36-8905-917730ddd37d">Cough and upper respiratory allergy symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cough and upper respiratory allergy symptoms:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Liquid:</p>
<p style="text-indent:-2em;margin-left:6em;">Brompheniramine 1 mg/phenylephrine 2.5 mg per 5 mL (eg, Dimetapp, Dimaphen, Rynex PE): Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to &lt;12 years: 10 mL every 4 hours as needed; maximum daily dose: 60 mL/<b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: 20 mL every 4 hours as needed; maximum daily dose: 120 mL/<b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Brompheniramine 2 mg/phenylephrine 5 mg per 5 mL (eg, Maxi-Tuss PE): Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to &lt;12 years: 5 mL every 4 hours as needed; maximum daily dose: 30 mL/<b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: 10 mL every 4 hours as needed; maximum daily dose: 60 mL/<b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Brompheniramine 4 mg and phenylephrine 10 mg per 5 mL (eg, Glenmax PEB): Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: 5 mL every 4 hours; maximum daily dose: 30 mL/<b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets:</p>
<p style="text-indent:-2em;margin-left:6em;">Brompheniramine 4 mg and phenylephrine 10 mg per tablet (eg, Ru-Hist D): Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to &lt;12 years: <sup>1</sup>/<sub>2</sub> tablet every 4 hours as needed; maximum daily dose: 3 tablets/<b>24 hours </b>(6 doses).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: 1 tablet every 4 hours as needed; maximum daily dose: 6 tablets/<b>24 hours</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090229"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51090230"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F7677174"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9070" href="/d/html/9070.html" rel="external">see "Brompheniramine and phenylephrine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="48cb75c5-6a62-486d-9adb-4acdfeee4b4e">Upper respiratory tract conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Upper respiratory tract conditions:</b>
<b>Oral:</b>
<b>Note:</b> These are general dosage guidelines; also refer to product specific dosing. All dosing is presented in terms of brompheniramine maleate and phenylephrine hydrochloride:</p>
<p style="text-indent:-2em;margin-left:2em;">Liquid:</p>
<p style="text-indent:-2em;margin-left:4em;">Brompheniramine 1 mg and phenylephrine 2.5 mg per 5 mL: 20 mL every 4 hours (maximum: 120 mL per 24 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Brompheniramine 2 mg and phenylephrine 5 mg per 5 mL: 10 mL every 4 hours (maximum: 60 mL per 24 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Brompheniramine 4 mg and phenylephrine 10 mg per 5 mL: 5 mL every 4 hours (maximum: 30 mL per 24 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Brompheniramine 4 mg and phenylephrine 10 mg per tablet: One tablet every 4 hours (maximum: 6 tablets per 24 hours).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992054"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989377"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F239195"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block coi drugH1Div" id="F239202"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication, do not use to sedate a child, or with or within 14 days of stopping monoamine oxidase inhibitor therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F239193"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Antihistamines may cause excitation in young children.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982); some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication (OTC), notify health care provider prior to use if you have breathing problems (eg, chronic bronchitis, asthma, emphysema), diabetes, glaucoma, heart disease, high blood pressure, thyroid disease, difficultly in urination due to enlargement of the prostate gland, or are currently taking sedatives, tranquilizers, or other oral nasal decongestants or stimulants. Discontinue use and notify health care provider if new symptoms occur, symptoms do not improve within 7 days or are accompanied by fever, rash, or persistent headache, or if nervousness, dizziness, or sleeplessness occur.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878683"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported (in some cases, high blood concentrations of pseudoephedrine were found). Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA does not recommend OTC uses for these products in pediatric patients &lt;2 years of age and recommends to use with caution in pediatric patients ≥2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018). Antihistamines should not be used to make an infant or child sleepy. Multiple concentrations of oral liquid formulations exist; close attention must be paid to the concentration when ordering or administering.</p>
<p style="text-indent:-2em;margin-left:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F239199"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Liquid, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Dimaphen Children's: Brompheniramine maleate 1 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL [DSC]) [ethanol free, gluten free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;">Dimetapp Children’s Cold &amp; Allergy: Brompheniramine maleate 2 mg and phenylephrine hydrochloride 5 mg per 10 mL (118 mL) [ethanol free; contains propylene glycol, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;">Glenmax PEB: Brompheniramine maleate 4 mg and phenylephrine hydrochloride 10 mg per 5 mL (473 mL) [alcohol free, dye free, sugar free; contains propylene glycol, saccharin sodium, sodium benzoate, sorbitol; fruit gum flavor]</p>
<p style="text-indent:-2em;margin-left:4em;">Rynex PE: Brompheniramine maleate 1 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (473 mL) [ethanol free, gluten free, sugar free; contains propylene glycol; bubblegum flavor]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Brompheniramine maleate 2 mg and phenylephrine hydrochloride 5 mg per 5 mL (118 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Brohist D: Brompheniramine maleate 4 mg and phenylephrine hydrochloride 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">Ru-Hist D: Brompheniramine maleate 4 mg and phenylephrine hydrochloride 10 mg</p></div>
<div class="block geq drugH1Div" id="F7675111"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16324138"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Elixir</b> (Dimetapp Cold/Allergy Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1-2.5 mg/5 mL (per mL): $0.05</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614047"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with an accurate measuring device; do not use a household teaspoon (overdosage may occur).</p></div>
<div class="block adm drugH1Div" id="F7677176"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Measure liquid doses using provided dosage cup only.</p></div>
<div class="block sts drugH1Div" id="F7677169"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at room temperature.</p></div>
<div class="block usep drugH1Div" id="F53569612"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Temporary relief of symptoms associated with the common cold, allergic rhinitis, and other upper respiratory allergies (OTC: FDA approved in pediatric patients ≥6 years and adults). <b>Note:</b> Approved ages and uses for generic products may vary; consult labeling for specific information.</p></div>
<div class="block mst drugH1Div" id="F46056526"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Brompheniramine, a first-generation antihistamine, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potent anticholinergic properties resulting in increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity; use should also be avoided due to reduced clearance with advanced age and tolerance associated with use as a hypnotic. Exposure to concurrent anticholinergic drugs also increases risk of falls, delirium, and dementia; consider total anticholinergic burden when conducting medication reviews (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block dic drugH1Div" id="F7677175"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products contain sodium.</p></div>
<div class="block pri drugH1Div" id="F54814476"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Refer to individual monographs.</p></div>
<div class="block phk drugH1Div" id="F7677170"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">See individual monograph for Phenylephrine.</p>
<p style="text-indent:-2em;margin-left:2em;">Brompheniramine component only:</p>
<p style="text-indent:-2em;margin-left:4em;">Distribution: V<sub>d</sub>: Mean: Children 6 to 12 years: 20 L/kg (Simons 1999); Adults: 11.7 L/kg (Simons 1982)</p>
<p style="text-indent:-2em;margin-left:4em;">Protein binding: 39% to 49% (Martínez-Gómez 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Metabolism: Hepatic, extensive (Simons 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Half-life elimination: Mean: Children 6 to 12 years: 12.4 hours (Simons 1999); Adults: 24.9 hours (Simons 1982)</p>
<p style="text-indent:-2em;margin-left:4em;">Time to peak, serum: Oral: Children 6 to 12 years: 3.2 hours (Simons 1999); Adults: 2 to 4 hours (Simons 1982)</p>
<p style="text-indent:-2em;margin-left:4em;">Excretion: Urine (50%, as inactive metabolites) (Bruce 1968)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50470350"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bialerge | Decongex plus</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Phenetaps</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dimetapp | Naseco-f | Unihist</span>;</li>
<li>
<span class="countryCode">(HN)</span> <span class="country">Honduras</span><span class="countrySeparator">: </span><span class="drugName">Coldex ad</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dimetapp infantil | Fempabix infantil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Tussinol-n</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bromitapp | Cold Aid | Dimeped | Dmt | Iruden | Mucotapp | Nazaclir | Pediatapp neo | Remedril | Snizee</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Brohist D | Bromax D | Brovex Adt | Entre B | Relhist bp | Respahist II | Ru hist d | Tanabid | Tanabid Da | V Hist | Vazobid pd</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aorinyl | Aorinyl-dec | Apracur Kids | Asiatapp | Bacoti t | Bepeno | Bro mapp 455 | Bromavon | Bromda | Bromesep | Bromiton | Bromped | Clinicold | Clinitapp | Cotapp | Denasal | Dimetapp | Extahis | Leffrin | Mcdyl | Meditapp | Mexy | Minra | Nartap | Nasifed bpo | Nasotapp | Piptapp | Postap | Rhinotapp | Sinufen | Topamine | Unihist</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Nosemin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brompheniramine-and-phenylephrine-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brompheniramine-and-phenylephrine-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. Available at http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/
                  </div>
</li>
<li>
<div class="reference">
                  Brohist D (phenylephrine hydrochloride and brompheniramine maleate) tablet [prescribing information]. Canton, MS: Allegis Pharmaceuticals; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4386938">
<a name="4386938"></a>Bruce RB, Turnbull LB, Newman JH, et al. Metabolism of brompheniramine. <i>J Med Chem</i>. 1968;11(5):1031-1034.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brompheniramine-and-phenylephrine-pediatric-drug-information/abstract-text/4386938/pubmed" id="4386938" target="_blank">4386938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17218934">
<a name="17218934"></a>Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. <i>MMWR Morb Mortal Wkly Rep</i>. 2007;56(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brompheniramine-and-phenylephrine-pediatric-drug-information/abstract-text/17218934/pubmed" id="17218934" target="_blank">17218934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brompheniramine-and-phenylephrine-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Children's Dimetapp Cold &amp; Allergy (brompheniramine maleate and phenylephrine hydrochloride) [prescribing information]. Warren, NJ: GSK Consumer Healthcare; received 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. Available at <a href="https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm" target="_blank">https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>Food and Drug Administration (FDA). OTC cough and cold products: not for infants and children under 2 years of age. January 17, 2008. Available at Food and Drug Administration (FDA). OTC cough and cold products: not for infants and children under 2 years of age. January 17, 2008. Available at <a href="http://www.fda.gov/forconsumers/consumerupdates/ucm048682.htm" target="_blank">http://www.fda.gov/forconsumers/consumerupdates/ucm048682.htm</a>. Last accessed January 29, 2015. Last accessed January 29, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.3">
<a name="FDA.3"></a>Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. Available at <a href="https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm" target="_blank">https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference">
                  Glenmax PEB (phenylephrine hydrochloride and brompheniramine maleate) syrup [prescribing information]. Villa Park, IL: Glendale Inc.; December 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brompheniramine-and-phenylephrine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17605150">
<a name="17605150"></a>Martínez-Gómez MA, Villanueva-Camañas RM, Sagrado S, et al, "Evaluation of Enantioselective Binding of Antihistamines to Human Serum Albumin by ACE," <i>Electrophoresis</i>, 2007, 28(15):2635-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brompheniramine-and-phenylephrine-pediatric-drug-information/abstract-text/17605150/pubmed" id="17605150" target="_blank">17605150</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Maxi-Tuss PE (brompheniramine maleate and phenylephrine hydrochloride) [prescribing information]. Brooksville, FL: MCR American Pharmaceuticals Inc; May 2020.</div>
</li>
<li>
<div class="reference">
                  Ru-Hist D (brompheniramine maleate and phenylephrine hydrochloride) [prescribing information]. Canton, MS: Allegis Pharmaceuticals, LLC; received 2020.</div>
</li>
<li>
<div class="reference">
                  Rynex PE (brompheniramine maleate and phenylephrine hydrochloride liquid) [prescribing information]. Ripley, MS: Edwards Pharmaceuticals, Inc.; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brompheniramine-and-phenylephrine-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15548781">
<a name="15548781"></a>Simons FE. Advances in H1-antihistamines. <i>N Engl J Med</i>. 2004;351(21):2203-2217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brompheniramine-and-phenylephrine-pediatric-drug-information/abstract-text/15548781/pubmed" id="15548781" target="_blank">15548781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6128358">
<a name="6128358"></a>Simons FE, Frith EM, Simons KJ. The pharmacokinetics and antihistaminic effects of brompheniramine.<i> J Allergy Clin Immunol</i>. 1982;70(6):458-464.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brompheniramine-and-phenylephrine-pediatric-drug-information/abstract-text/6128358/pubmed" id="6128358" target="_blank">6128358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9949311">
<a name="9949311"></a>Simons FE, Roberts JR, Gu X, et al. The clinical pharmacology of brompheniramine in children. <i>J Allergy Clin Immunol</i>. 1999; 103(2, pt 1):223-226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brompheniramine-and-phenylephrine-pediatric-drug-information/abstract-text/9949311/pubmed" id="9949311" target="_blank">9949311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brompheniramine-and-phenylephrine-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 118053 Version 54.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
